|
|
|
Insider
Information: |
Love Ted W |
Relationship: |
Director |
City: |
Sunnyvale |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
10 |
|
Direct
Shares |
252,099 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$2,618,945 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
252,099 |
|
|
Total
Value |
$2,618,945 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Nuvelo Inc |
ABIO |
Director |
2008-05-30 |
3,580 |
2004-02-27 |
0 |
Premium* |
|
Onyx Pharmaceuticals Inc |
ONXX |
EVP, R&D and Tech. Ope... |
2012-07-25 |
77,756 |
2010-02-01 |
0 |
Premium* |
|
Santarus Inc |
SNTS |
Director |
2014-01-02 |
0 |
2012-03-09 |
0 |
Premium* |
|
Amicus Therapeutics Inc |
FOLD |
Director |
2020-06-04 |
131,000 |
2014-03-12 |
0 |
Premium* |
|
Global Blood Therapeutics, Inc. |
GBT |
President and CEO, Dir... |
2022-10-05 |
0 |
2022-10-05 |
0 |
Premium* |
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2015-09-05 |
0 |
Premium* |
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2020-07-02 |
0 |
2019-09-18 |
0 |
Premium* |
|
Royalty Pharma Plc |
RPRX |
Director |
2023-06-23 |
36,941 |
|
0 |
Premium* |
|
Seagen Inc |
SGEN |
|
2023-12-14 |
0 |
2020-08-17 |
0 |
Premium* |
|
Gilead Sciences Inc |
GILD |
Director |
2024-05-08 |
2,822 |
2024-02-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
123 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ONXX |
Onyx Pharmaceuticals Inc |
EVP, R&DOfficer |
|
2010-02-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,350 |
|
- |
|
GBT |
Global Blood Therapeutics... |
See RemarksOfficer |
|
2015-08-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,135,711 |
|
- |
|
RPRX |
Royalty Pharma Plc |
Director |
|
2020-07-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,000 |
|
% |
|
ABIO |
Nuvelo Inc |
President and C.E.O. |
|
2004-02-27 |
4 |
A |
$10.45 |
$7,346 |
D/D |
703 |
703 |
|
- |
|
ABIO |
Nuvelo Inc |
President and C.E.O. |
|
2004-05-28 |
4 |
A |
$7.40 |
$7,393 |
D/D |
999 |
999 |
|
- |
|
ABIO |
Nuvelo Inc |
President and C.E.O. |
|
2004-08-31 |
4 |
A |
$7.57 |
$2,733 |
D/D |
361 |
361 |
|
- |
|
ABIO |
Nuvelo Inc |
President and C.E.O. |
|
2005-05-31 |
4 |
A |
$6.30 |
$14,981 |
D/D |
2,378 |
2,378 |
|
- |
|
ABIO |
Nuvelo Inc |
C.E.O. |
|
2005-08-31 |
4 |
A |
$6.33 |
$5,779 |
D/D |
913 |
3,291 |
|
- |
|
ABIO |
Nuvelo Inc |
C.E.O. |
|
2006-05-31 |
4 |
A |
$13.90 |
$15,735 |
D/D |
1,132 |
4,423 |
|
- |
|
ABIO |
Nuvelo Inc |
C.E.O. |
|
2006-08-31 |
4 |
A |
$14.20 |
$4,146 |
D/D |
292 |
21,042 |
0 |
- |
|
ABIO |
Nuvelo Inc |
C.E.O. |
|
2007-05-31 |
4 |
A |
$2.90 |
$16,374 |
D/D |
5,649 |
26,691 |
0 |
- |
|
ABIO |
Nuvelo Inc |
C.E.O. |
|
2007-08-31 |
4 |
A |
$1.85 |
$2,961 |
D/D |
1,598 |
28,289 |
0 |
- |
|
ABIO |
Nuvelo Inc |
C.E.O |
|
2008-03-24 |
4 |
B |
$0.67 |
$19,479 |
D/D |
29,000 |
57,289 |
2.81 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
EVP, R&D |
|
2010-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,500 |
31,850 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
EVP, R&D and Tech. Operations |
|
2011-02-01 |
4 |
D |
$35.82 |
$75,688 |
D/D |
(2,113) |
29,737 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
EVP, R&D and Tech. Operations |
|
2011-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
28,500 |
58,237 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
EVP, R&D and Tech. Operations |
|
2012-02-01 |
4 |
D |
$41.98 |
$88,074 |
D/D |
(2,098) |
56,804 |
0 |
- |
|
SNTS |
Santarus Inc |
Director |
|
2012-03-09 |
4 |
OE |
$1.18 |
$319,775 |
D/D |
150,500 |
150,500 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
EVP, R&D and Tech. Operations |
|
2012-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
26,950 |
83,754 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
EVP, R&D and Tech. Operations |
|
2012-04-02 |
4 |
D |
$36.58 |
$27,689 |
D/D |
(757) |
82,997 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
EVP, R&D and Tech. Operations |
|
2012-07-25 |
4 |
AS |
$73.97 |
$387,687 |
D/D |
(5,241) |
77,756 |
0 |
- |
|
SNTS |
Santarus Inc |
Director |
|
2012-12-18 |
4 |
B |
$10.88 |
$2,012,800 |
D/D |
185,000 |
335,500 |
2.39 |
- |
|
SNTS |
Santarus Inc |
Director |
|
2014-01-02 |
4 |
D |
$32.00 |
$10,736,000 |
D/D |
(335,500) |
0 |
0 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2014-03-12 |
4 |
A |
$2.21 |
$243,100 |
D/D |
110,000 |
110,000 |
0 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2014-11-25 |
4 |
A |
$7.83 |
$250,637 |
D/D |
32,000 |
142,000 |
0 |
- |
|
123 Records found
|
|
Page 1 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|